New Drug Shows Benefit in NET Carcinoid SyndromeNew Drug Shows Benefit in NET Carcinoid Syndrome

Telotristat etiprate is the first drug developed specifically for carcinoid syndrome, which occurs in patients with metastatic neuroendocrine tumors (NETs). Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news